接受肽受体放射性核素治疗的患者中肠系膜或腹膜疾病患者的肠梗阻风险
该研究回顾了2018年4月至2019年10月在Moffitt癌症中心接受177Lu-DOTATATE治疗的患者记录,评估肠系膜或腹膜疾病患者在接受肽受体放射性核素治疗后3个月内发生肠梗阻的风险。159例患者中81例有基线肠系膜或腹膜疾病,其中5例(6%)在治疗后3个月内发生至少一次肠梗阻,所有5例对大剂量皮质类固醇治疗至少有暂时反应并恢复肠道功能,但2例最终死于进展性腹膜疾病。作者认为肽受体放射性核素治疗可能通过诱发炎症导致肠梗阻,皮质类固醇可能在治疗和预防中发挥作用。
要点
- 81例有基线肠系膜或腹膜疾病的患者中,5例(6%)在177Lu-DOTATATE治疗后3个月内发生至少一次肠梗阻。
- 2例患者在梗阻期间接受手术探查,描述为「冰冻腹」。
- 所有5例对大剂量皮质类固醇治疗至少有暂时反应并恢复肠道功能,但2例最终死于进展性腹膜疾病。
核心结论
- 肽受体放射性核素治疗可能导致肠系膜或腹膜疾病患者发生肠梗阻,可能通过诱发炎症。
- 皮质类固醇可能在治疗和预防中发挥作用。
研究设计与样本
- 回顾性评估2018年4月至2019年10月在Moffitt癌症中心接受177Lu-DOTATATE治疗的所有患者记录。
- 将177Lu-DOTATATE治疗后3个月内发生肠梗阻的患者数除以有既存腹膜或肠系膜疾病的总患者数。
- 评估管理策略和结局。
主要发现
- 共159例患者接受治疗,其中81例有基线肠系膜或腹膜疾病。
- 81例有基线肠系膜或腹膜疾病的患者中,5例(6%)在治疗后3个月内发生至少一次肠梗阻。
- 2例患者在梗阻期间接受手术探查,描述为「冰冻腹」。
- 所有5例对大剂量皮质类固醇治疗至少有暂时反应并恢复肠道功能,但2例最终死于进展性腹膜疾病。
临床怎么用
- 作者认为肽受体放射性核素治疗可能通过诱发炎症导致肠系膜或腹膜疾病患者发生肠梗阻。
- 作者认为皮质类固醇可能在治疗和预防中发挥作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although radiation-induced mesenteritis or peritonitis can potentially exacerbate the risk of bowel obstruction, there are no data in the literature on the incidence of intestinal obstruction related to peptide receptor radionuclide therapy. Methods: The records of all patients treated with 177Lu-DOTATATE at Moffitt Cancer Center between April 2018 and October 2019 were evaluated. The number of patients who developed bowel obstruction within 3 mo of a 177Lu-DOTATATE treatment was divided by the total number of patients with preexisting peritoneal or mesenteric disease. Management strategies and outcomes were evaluated. Results: Of a total of 159 patients treated, 81 had baseline mesenteric or peritoneal disease, among whom 5 (6%) experienced at least 1 episode of bowel obstruction within 3 mo of treatment. Two of the patients underwent surgical exploration during obstruction describing a "frozen abdomen." All 5 responded at least temporarily to high-dose corticosteroid treatment and regained bowel function, but 2 patients eventually succumbed to progressive peritoneal disease. Conclusion: Peptide receptor radionuclide therapy can lead to bowel obstruction in patients with mesenteric or peritoneal disease, likely by inducing inflammation. Corticosteroids can potentially play a role in treatment and prophylaxis.
引用
- Strosberg JR, Al-Toubah T, Pellè E, et al. Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy. J Nucl Med. 2020. PMID: 32444368. doi:10.2967/jnumed.120.242875
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。